{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.3","upperLimit":"50.3","value":"44.2"},{"groupId":"OG001","lowerLimit":"70.4","upperLimit":"80.7","value":"75.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"281"}],"units":"Participants"}],"description":"VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \\>=90% reduction in serum M-protein plus urine M-protein \\<100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \\>90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a \\>=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \\<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg weekly for participants greater than \\[\\>\\] 75 years old or with a body mass index less than \\[\\<\\] 18.5 kilograms per meter square \\[kg/m\\^2\\]).","id":"OG000","title":"Lenalidomide, Low-dose Dexamethasone (Rd)"},{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks, each 28-day cycle); once only on Day 1 during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone was administered at a total dose of 40 mg weekly (or 20 mg weekly for participants \\>75 years old or with a body mass index \\< 18.5 kg/m\\^2).","id":"OG001","title":"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)"}],"paramType":"NUMBER","populationDescription":"Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression (up to 21 months)","title":"Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better","type":"SECONDARY","unitOfMeasure":"percentage of participants"}